Knowledge HQ

GMP Recombinant Human IL-2 joins IL-7 and IL-15 produced within Bio-Techne’s dedicated animal-free GMP facility located in St. Paul MN USA. Our GMP-grade IL-2 contains the same cysteine to serine mutation found in Proleukin®. This mutation has been reported to prevent cysteine mispairing in E.coli, which can lead to protein aggregation and makes our new GMP-grade IL-2 protein soluble in injectable-grade water.

IL-2, IL-7, and IL-15 are critical cytokine components to many successful T and NK cell therapy programs.  Choosing these cytokines from a partner that can offer seamless translation from RUO to GMP means that the consistency across lots, the confidence in bioactivity, and cost-effectiveness are no longer barriers to manufacturing with consistency, translating with speed and scaling without limitation.  Learn more about these powerhouse cytokines in this brochure.

Key features of the Cue Cell Processing System include flexibility - user-defined aliquot container number and fill volume, all-in-one - ability to concentrate and wash in the same procedure as final formulate and fill, precision - aliquot volumes ≤10 mL, and control - optional automated temperature control and mixing.

Whether you’re focused on early-stage trials or ramping up to full commercialization, Lovo’s spinning membrane filtration technology enables fast, precise, and flexible procedures that help increase your lab’s overall operational efficiency and processing consistency without compromising product quality.

The benefits of non-viral gene engineering, when compared with its viral counterpart, offer simplicity, and streamlined capabilities all while lowering risk and cost. TcBuster as part of the ScaleReady portfolio empowers cell therapy programs to move to market faster and with superior scalability ensuring confidence in reproducibility, bench to bedside.

Within cell therapy manufacturing, GMP ancillary materials like cytokines are used as essential cell culture supplements to produce cell-based medicines. The success of the cell therapy will depend on the quality and consistency of these ancillary materials, making the choice of supplier a crucial decision to get right.

The rapid response and deployment of our Field Service and Support team are crucial to your process. This flyer is for Lovo and Cue customers who are looking to ensure that you have the support you need when you need it through Fresenius Kabi technical and customer service channels.

This technical video describes how Cue Cell Processing System combines its innovative spinning membrane technology with unique fluid dynamics to provide automated, closed-system small volume cell processing with unmatched precision. Cue enables high accuracy concentration, formulation, and aliquoting for cell therapy manufacturing. Applications include cryopreservation preparation, electroporation preparation, and fill/finish.

This technical video describes how Lovo Cell Processing System uses its innovative spinning membrane technology to delivers automated, functionally closed processing for cell therapy manufacturing. Lovo's spinning membrane, combined with software that enables flexible input volumes and cell concentration outputs, is used for various closed-system cell processing applications, including leukapheresis wash, immunomagnetic separation preparation, cultured cell concentration, and thawed product DMSO removal.

In this case study we interview Arindam Mitra, Head of Advanced Therapies Manufacturing at Guy's and St. Thomas, Biomedical Research Center, on their use of the Lovo cell processing system to support manufacturing of a COVID-19 cell therapy to treat lung fibrosis. This cell therapy is currently in clinical trials. A BBC video describing the manufacturing procedure and treatment impact on one patient is included.

GMP-grade Recombinant Human IL-7 can now be produced at a game-changing scale within Bio-Techne’s new dedicated animal-free GMP facility. This flyer details manufacturing benefits and product specifications for GMP IL-7, including comparison to animal-free research-grade rhIL-7 to enable a seamless transition to GMP.

In this case study, ScaleReady helped an autologous T cell therapy company rapidly transition to a closed-system process for cell expansion by providing a testing plan to verify that G-Rex500M-CS closed-system bioreactors would meet their immediate cell production requirements and improve cell production efficiency, while adhering to their short timelines for going into clinical trials. In doing so, the company also uncovered small changes to their cell culture protocols that made a big impact on their cell production efficiency.